2096 — Simcere Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- HK$25.84bn
- HK$25.03bn
- CNY6.64bn
- 85
- 24
- 96
- 80
Annual income statement for Simcere Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4,509 | 5,000 | 6,324 | 6,608 | 6,635 |
| Cost of Revenue | |||||
| Gross Profit | 3,609 | 3,920 | 4,997 | 4,984 | 5,325 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3,582 | 3,551 | 5,463 | 5,896 | 5,787 |
| Operating Profit | 927 | 1,449 | 861 | 712 | 848 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 805 | 1,402 | 886 | 740 | 820 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 664 | 1,499 | 927 | 714 | 733 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 670 | 1,507 | 931 | 715 | 733 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 670 | 1,507 | 931 | 715 | 733 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.289 | 0.477 | 0.358 | 0.085 | 0.291 |
| Dividends per Share |